News about Global Pharma

Emcure Launches New Entity Emcutix Biopharmaceuticals for Dermatology Sector

As a part of this strategic initiative, Emcure's existing dermatology business will also operate under Emcutix.

Global Pharma | 29/10/2024 | By Aishwarya |  1129

Indegene Achieves Revenue of INR 6,868 Million in Q2FY25

In the second quarter of the financial year 2025, Indegene achieved revenue from operations totaling INR 6,868 million, marking an 8.0 percent Year-over-Year (YoY) growth compared to the same period in the previous year.

Global Pharma | 29/10/2024 | By Aishwarya |  927

LakeShore Biopharma Gets Phase III Clinical Trial Approval for YSJA Rabies Vaccine

The Trial, which is expected to begin in December 2024, will evaluate the immunogenicity and safety of the YSJA rabies vaccine across two distinct four-dose immunization schedules to determine their immunogenicity and safety compared to the existing Essen regimen (1-1-1-1-1).

Global Pharma | 28/10/2024 | By Aishwarya |  705

PhotonPharma Welcomes Derek Brown as its New CEO

With more than 25 years of diverse biopharmaceutical experience across the entire product lifecycle, Derek brings a wealth of strategic, operational, and financial expertise to guide PhotonPharma through its next phase of growth.

Global Pharma | 28/10/2024 | By Aishwarya |  405

Sun Pharma Presents LEQSELVITM Data at 2024 Fall Clinical Dermatology Conference

LEQSELVI data presented at Fall Clinical includes pooled long-term results from open-label extension (OLE) studies showing ongoing and clinically meaningful improvements in scalp hair regrowth in adults with AA taking LEQSELVI for up to 68 weeks.

Global Pharma | 28/10/2024 | By Aishwarya |  573

AbbVie and Gedeon Richter to Develop Novel Targets for Neuropsychiatric Conditions

This collaboration expands upon the success of nearly two decades of partnership on central nervous system (CNS) projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA) and the discovery of investigational drug candidate ABBV-932 for the treatment of bipolar depression and generalized anxiety disorder.

Global Pharma | 25/10/2024 | By Aishwarya |  274

Ocuphire Pharma Announces Acquisition of Opus Genetics

The merger creates a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of IRDs.

Global Pharma | 24/10/2024 | By Aishwarya |  521

Sterline Asia Announces its Participation in CPHI & PMEC INDIA 2024

Steriline is dedicated to developing equipment that not only meets the needs of today’s pharmaceutical industry but also contributes to a more sustainable future for the pharmaceutical industry.

Global Pharma | 24/10/2024 | By Aishwarya |  491

Lupin Announces Appointment of Claus Jepsen as President-Global Specialty

Claus joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for Rare Diseases.

Global Pharma | 22/10/2024 | By Aishwarya |  467

JB Pharma Releases its Third Sustainability Report FY24

JB Pharma’s third sustainability report highlights the company’s achievements in reducing its environmental impact and improving resource efficiency.

Global Pharma | 22/10/2024 | By Aishwarya |  726